Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Articolo in rivista) (literal)

Anno

• 2010-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1148/radiol.09090603 (literal)

Alternative label

• Giovanni Storto; Amalia De Renzo; Teresa Pellegrino; Fabiana Perna; Teresa De Falco; Paola Erra; Anna Nardelli; Antonio Speranza; Michele Klain; Bruno Rotoli; Leonardo Pace. (2010)
  Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
  in Radiology; Radiological Society of North America, Oak Brook (Stati Uniti d'America)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Giovanni Storto; Amalia De Renzo; Teresa Pellegrino; Fabiana Perna; Teresa De Falco; Paola Erra; Anna Nardelli; Antonio Speranza; Michele Klain; Bruno Rotoli; Leonardo Pace. (literal)

Pagina inizio

• 245 (literal)

Pagina fine

• 252 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

• http://radiology.rsna.org/content/254/1/245.long#content-block (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 254 (literal)

Rivista

• Radiology (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

• 8 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 1 (literal)

Note

• ISI Web of Science (WOS) (literal)
• Scopu (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata,Rionero in Vulture, Italy (G.S.), Dipartimento di Biochimica e Biotecnologie Mediche (A.D.R., F.P., B.R.), Instituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (T.P., A.S.), Dipartimento di Scienze Biomorfologiche e Funzionali (P.E., A.N., M.K., L.P.), Università \"Federico II,\" Via Pansini 5, 80131 Naples, Italy, IRCCS, Fondazione Istituto di Diagnostica Nucleare, Naples, Italy (T.D.F., L.P.). (literal)

Titolo

• Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (literal)

Abstract

• Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 ( 90 Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fl uorine 18 ( 18 F) fl uorodeoxyglucose (FDG) combined positron emission tomographic- computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twentythree consecutive patients (10 women, 13 men; mean age, 51.8 years 6 7.3 [standard deviation ]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18 F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete ( n = 12) or partial ( n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These fi ndings were all confi rmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% ( P , .05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identifi cation of patients needing additional therapeutic strategies. (literal)

Editore

• Radiological Society of North America (Editore)

Prodotto di

• Institute of biostructure and bioimaging (IBB) (Istituto)
• Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi (ME.P03.001.001) (Modulo)

Autore CNR

• ANTONIO SPERANZA (Unità di personale interno)
• GIOVANNI STORTO (Unità di personale interno)
• TERESA PELLEGRINO (Unità di personale interno)

Incoming links:

Autore CNR di

• ANTONIO SPERANZA (Unità di personale interno)
• GIOVANNI STORTO (Unità di personale interno)
• TERESA PELLEGRINO (Unità di personale interno)

Prodotto

• Institute of biostructure and bioimaging (IBB) (Istituto)
• Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi (ME.P03.001.001) (Modulo)

Editore di

• Radiological Society of North America (Editore)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Radiology (Rivista)